Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00003752 | Bexarotene in Treating Patients With Metastatic Breast Cancer | PHASE2 | COMPLETED | 180 | — | — | Oct 1, 1998 | Mar 1, 2003 | May 30, 2013 | 30 | United States |
| Name | Type | Description |
|---|---|---|
| bexarotene | DRUG | - |
DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer No CNS metastases No rapidly progressing visceral disease Previously irradiated lesions(s) may be designated as measurable indicator tumor(s) only if more than 6 months since radiotherapy, patient has no other measurable dise...